163 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
) and evidence of type 2 inflammation. A regulatory application is also under review in the European Union (EU) and Japan.
A Phase 3 study for Dupixent
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
application has also been submitted in the European Union (EU).
In January 2024, the FDA approved Dupixent for the treatment of children aged 1 to 11 years
8-K
EX-99.1
wgk2p2 pdsbgjm5
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
8-K
EX-99.1
opkdu8
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-10.1
wvus4vf
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
ww1x nm4j
20 Dec 22
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-99.1
8tuqpfb
3 Aug 22
Regeneron Reports Second Quarter 2022 Financial and Operating Results
7:08am
8-K
EX-99.1
ba8l63q8 63
4 May 22
Regeneron Reports First Quarter 2022 Financial and Operating Results
7:08am
DEFA14A
hqoi0l2mn 0v
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-10.1
chpy67v54 5ver5b17
8 Mar 22
Entry into a Material Definitive Agreement
6:15am